This pilot study will investigate the use of PSMA-PET/MRI (Positron Emission Tomography/ Magnetic Resonance Imaging)to guide radiation treatment planning in patients with known or suspected locally metastatic prostate cancer at the time of diagnosis. Patients will undergo a single PSMA-PET/MRI (or PET/CT (Computed Tomography) in some circumstances) prior to initiation of treatment. Following development of a PSMA-PET guided radiation treatment plan, therapeutic radiation will be delivered per standard-of-care parameters and assessments of feasibility and tolerability will be performed.
Biopsy-proven treatment-naïve prostate adenocarcinoma with pelvic metastases known to suspected on standard-of-care staging imaging Eligibility and plan to undergo definitive radiation therapy for prostate cancer per established standard-of-care radiation oncology clinical guidelines Be at least 18 years of age
Exclusion Criteria:
Inability to tolerate or undergo PET/MRI or PET/CT Previous or current hematologic or lymphatic disorder (including leukemia, lymphoma, Castleman's disease, etc.) Recurrent prostate adenocarcinoma Known distant metastatic disease Current or prior treatment for prostate cancer Known allergy to glucagon Previous diagnosis of insulinoma or pheochromocytoma
